Cara Therapeutics, Inc. (NASDAQ:CARA – Get Free Report) has been given an average recommendation of “Hold” by the six ratings firms that are presently covering the company, MarketBeat Ratings reports. Six research analysts have rated the stock with a hold recommendation. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $3.93.
Several research firms have recently weighed in on CARA. StockNews.com assumed coverage on shares of Cara Therapeutics in a research note on Thursday, August 1st. They issued a “sell” rating for the company. Canaccord Genuity Group downgraded shares of Cara Therapeutics from a “buy” rating to a “hold” rating and decreased their price target for the company from $10.00 to $1.00 in a research note on Thursday, June 13th. Needham & Company LLC lowered shares of Cara Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, June 13th. HC Wainwright downgraded Cara Therapeutics from a “buy” rating to a “neutral” rating in a research note on Thursday, June 13th. Finally, Stifel Nicolaus downgraded Cara Therapeutics from a “buy” rating to a “hold” rating and dropped their price target for the stock from $6.00 to $1.00 in a research note on Thursday, June 13th.
Read Our Latest Stock Analysis on Cara Therapeutics
Institutional Investors Weigh In On Cara Therapeutics
Cara Therapeutics Price Performance
Shares of NASDAQ CARA opened at $0.36 on Friday. The stock has a market capitalization of $19.78 million, a PE ratio of -0.16 and a beta of 0.69. Cara Therapeutics has a fifty-two week low of $0.24 and a fifty-two week high of $3.27. The business has a fifty day moving average price of $0.40 and a two-hundred day moving average price of $0.63.
Cara Therapeutics (NASDAQ:CARA – Get Free Report) last posted its quarterly earnings results on Monday, May 13th. The biopharmaceutical company reported ($0.56) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.18). Cara Therapeutics had a negative net margin of 723.49% and a negative return on equity of 174.15%. The company had revenue of $2.14 million during the quarter, compared to analyst estimates of $2.25 million. On average, equities analysts expect that Cara Therapeutics will post -1.28 EPS for the current year.
About Cara Therapeutics
Cara Therapeutics, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.
Further Reading
- Five stocks we like better than Cara Therapeutics
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- Uber’s Earnings Beat: Rideshare and Delivery Surge
- Investing in large cap stocks: Diving into big caps
- Hims & Hers Reports Stellar Quarter: Stock Set for a Rally
- How to Use Stock Screeners to Find Stocks
- Cloudflare Stock Flares Up on Solid EPS Beat and Raised Guidance
Receive News & Ratings for Cara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.